Cadrenal Therapeutics Future Growth
Future criteria checks 0/6
Cadrenal Therapeutics's earnings are forecast to decline at 21.5% per annum. EPS is expected to grow by 30.2% per annum.
Key information
-21.5%
Earnings growth rate
30.2%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -12 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -10 | N/A | N/A | 3 |
| 12/31/2024 | N/A | -9 | N/A | N/A | 3 |
| 9/30/2024 | N/A | -8 | -6 | -6 | N/A |
| 6/30/2024 | N/A | -6 | -5 | -5 | N/A |
| 3/31/2024 | N/A | -5 | -4 | -4 | N/A |
| 12/31/2023 | N/A | -8 | -4 | -4 | N/A |
| 9/30/2023 | N/A | -13 | -3 | -3 | N/A |
| 6/30/2023 | N/A | -13 | -3 | -3 | N/A |
| 3/31/2023 | N/A | -12 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVKD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CVKD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CVKD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if CVKD's revenue is forecast to grow faster than the US market.
High Growth Revenue: CVKD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CVKD's Return on Equity is forecast to be high in 3 years time